Skip to article
Astra

Pulmonology

Restrictive Lung Disease

Confirm true restriction with total lung capacity, then separate intrinsic parenchymal disease from obesity, neuromuscular, chest-wall, and pleural causes using diffusion capacity, imaging, oxygenation, and targeted etiologic testing.

Clinical question: How should clinicians confirm, classify, and evaluate restrictive lung disease while identifying patients who require ILD-center referral or transplant assessment?
Updated August 24, 20266 minute readPulmonology

First decision

Confirm restriction before assigning an ILD diagnosis

Reduced FVC is not synonymous with restrictive lung disease.

Confirm restriction with full lung volumes: a restrictive ventilatory defect is defined physiologically by reduced total lung capacity (TLC). Spirometry may show reduced FVC, but reduced FVC alone can reflect poor effort, airflow obstruction with air trapping, or extrapulmonary mechanical limitation; obtain plethysmographic lung volumes when feasible. PubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelfpubs rsnaPulmonary Function Tests for the Radiologist

Order DLCO, corrected for hemoglobin where feasible, with spirometry and lung volumes. In intrinsic parenchymal restriction, reduced TLC commonly accompanies impaired diffusion capacity; integrate DLCO with HRCT rather than using it as a stand-alone etiologic test. PubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelfpubs rsnaPulmonary Function Tests for the Radiologist

Obtain resting pulse oximetry and an exertional assessment, preferably a 6-minute walk test (6MWT), at baseline when ILD is suspected. The 6MWT supplies oxygenation and functional data that complement resting PFTs and should be repeated for disease monitoring when clinically indicated. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfPubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )cdn clinicaltrials'-1lll1v Ingelheim

Physiologic patterns that redirect the restrictive-lung-disease differential. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelfpubs rsnaPulmonary Function Tests for the Radiologist
PatternInterpretationNext action
Reduced FVC without documented low TLCRestriction is unconfirmed; spirometry alone is insufficient. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfObtain lung volumes, ideally plethysmography, and DLCO. PubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )PubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf
Reduced TLC plus low DLCOSupports intrinsic parenchymal restriction when concordant with imaging and clinical findings. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelfpubs rsnaPulmonary Function Tests for the RadiologistObtain HRCT and pursue a structured ILD evaluation. PubMedRestrictive Lung Disease - StatPearls - NCBI Bookshelf
Reduced TLC with isolated low ERV in obesityPattern may reflect obesity-related mechanical limitation. PubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfAssess for a second process if DLCO is reduced, hypoxemia is disproportionate, or imaging is abnormal. PubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf
Reduced TLC and VC with preserved RVRaises concern for neuromuscular weakness. PubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfEvaluate neuromuscular and diaphragmatic causes rather than assuming intrinsic lung fibrosis. PubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf
Reduced TLC with chest-wall or pleural abnormalitySuggests extrapulmonary restriction. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfDefine the structural cause with imaging and direct management to the chest-wall or pleural disorder. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf

Diagnostic branch point

Use HRCT and exposure-directed testing to classify intrinsic restriction

The highest-yield distinction is intrinsic ILD versus extrapulmonary restriction.

For confirmed or strongly suspected intrinsic restriction, obtain high-resolution CT (HRCT) of the chest and compare with prior imaging. In IPF, HRCT can show basal and posterior-predominant reticulation early and peripheral/subpleural honeycombing with traction bronchiectasis in advanced disease; imaging pattern and distribution direct the next diagnostic branch. PubMedRestrictive Lung Disease - StatPearls - NCBI Bookshelf

Take a structured exposure and medication history before classifying fibrosis as idiopathic: document cigarette exposure, environmental and occupational exposures, medication exposure, family history, and timing of symptoms relative to these risks. These exposures are routinely captured in IPF evaluation because they can identify an alternative cause of fibrosing lung disease. cdn clinicaltrials'-1lll1v Ingelheim

If connective-tissue disease is plausible clinically, obtain targeted autoimmune testing and assess for systemic features rather than relying on pulmonary physiology alone. CTD-related ILD assessment is complicated by extrapulmonary comorbidities that can confound measures of pulmonary activity and severity; interpret dyspnea, walk limitation, and PFT change in that context. BMJConnective tissue disease related interstitial lung ... - ThoraxPubMedRestrictive Lung Disease - StatPearls - NCBI Bookshelf

Actionable etiologic branches after confirmed intrinsic restrictive physiology. BMJConnective tissue disease related interstitial lung ... - ThoraxPubMedCurrent diagnosis, epidemiology, and management of interstitial lung abnormalitiesPubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfPubMedNonspecific Interstitial Pneumonia - StatPearls - NCBI Bookshelfcdn clinicaltrials'-1lll1v IngelheimclinicaltrialsStudy Details | NCT06855329 | PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis | ClinicalTrials.govclinicaltrialsStudy Details | NCT06416163 | FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion | ClinicalTrials.gov
Clinical-radiologic branchDiscriminatorsNext diagnostic step
Idiopathic pulmonary fibrosis/UIP considerationOlder adult with unexplained bilateral fibrosis, bibasilar crackles, restrictive physiology, and HRCT showing basal-posterior and peripheral/subpleural fibrotic change, honeycombing, or traction bronchiectasis. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfExclude alternative causes; use multidisciplinary review and consider biopsy only if HRCT-clinical integration is not diagnostic. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf
CTD-associated ILDSystemic CTD features or targeted autoantibody findings with compatible ILD; nonpulmonary comorbidities can confound severity assessment. BMJConnective tissue disease related interstitial lung ... - ThoraxPubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfIntegrate rheumatologic assessment, HRCT, PFT trajectory, and oxygenation rather than interpreting dyspnea alone. BMJConnective tissue disease related interstitial lung ... - ThoraxPubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )
Fibrotic hypersensitivity pneumonitis or exposure-related ILDRelevant environmental, occupational, or drug exposure temporally linked to lung disease. cdn clinicaltrials'-1lll1v IngelheimclinicaltrialsStudy Details | NCT06855329 | PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis | ClinicalTrials.govIdentify and remove the implicated exposure and use HRCT plus multidisciplinary assessment to establish the ILD subtype. PubMedInterstitial Lung Disease - StatPearls - NCBI Bookshelfcdn clinicaltrials'-1lll1v IngelheimclinicaltrialsStudy Details | NCT06855329 | PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis | ClinicalTrials.gov
NSIPDiagnosis of exclusion; pathology shows temporally homogeneous inflammation and fibrosis without UIP-type fibroblastic foci or peripheral accentuation. PubMedNonspecific Interstitial Pneumonia - StatPearls - NCBI BookshelfSearch for secondary causes, particularly CTD, before calling NSIP idiopathic. PubMedNonspecific Interstitial Pneumonia - StatPearls - NCBI Bookshelf
Interstitial lung abnormalityIncidental bilateral nondependent interstitial abnormality involving at least 5% of a lung zone, with or without fibrotic features. PubMedCurrent diagnosis, epidemiology, and management of interstitial lung abnormalitiesCompare prior imaging, classify fibrotic versus nonfibrotic ILA, and determine whether symptoms, impaired physiology, or a defined ILD diagnosis reclassify the patient as clinical ILD. PubMedCurrent diagnosis, epidemiology, and management of interstitial lung abnormalities

When HRCT does not settle the diagnosis

Refer cases with discordant clinical, radiologic, and pathologic findings—or persistent diagnostic uncertainty after comprehensive noninvasive evaluation—to an ILD multidisciplinary discussion involving pulmonology, thoracic radiology, and pathology. Interdisciplinary discussion is the diagnostic reference standard for ILD and is specifically recommended when HRCT and histology are nondiagnostic or discordant. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfThe LancetMulticentre evaluation of multidisciplinary team meeting ...

Select tissue sampling only if it is expected to change diagnostic confidence or management. Surgical lung biopsy is considered when IPF cannot be confirmed noninvasively and clinical-radiologic findings are incongruent with UIP, provided procedural risk is acceptable. Traditional transbronchial forceps biopsies have low yield for diffuse ILD; cryobiopsy may be used at experienced ILD centers, with an approximately 70% to 80% diagnostic yield and lower procedural risk than video-assisted thoracoscopic surgery. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfPubMedNonspecific Interstitial Pneumonia - StatPearls - NCBI Bookshelf

Risk stratification

Measure physiologic decline and identify advanced fibrosing disease early

Use serial function, exertional oxygenation, and imaging—not symptoms alone—to determine progression.

Establish a baseline that includes FVC, TLC, hemoglobin-corrected DLCO, resting oxygen saturation, and 6MWT. Serial change in FVC and DLCO, worsening exertional oxygenation, declining 6MWT distance, and interval HRCT progression provide complementary evidence of progressive fibrosing disease; symptoms may be confounded by cardiac, musculoskeletal, rheumatologic, or other comorbid conditions. BMJConnective tissue disease related interstitial lung ... - ThoraxPubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfPubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )cdn clinicaltrials'-1lll1v Ingelheim

Assess for acute clinical deterioration promptly in established IPF or fibrosing ILD. A commonly used acute-exacerbation framework includes deterioration within 30 days, new bilateral ground-glass opacities or consolidation superimposed on a reticular or honeycomb UIP background, and exclusion of pulmonary infection and alternative causes of acute worsening. cdn clinicaltrials[PDF] Galactic-1 Study Protocol - Clinical Trials

Refer early for lung-transplant evaluation in IPF and other progressive ILD rather than waiting for end-stage respiratory failure. Listing consideration includes FVC below 80% predicted with decline, DLCO below 40% predicted, 6MWT distance below 250 m or declining, or an acute ILD exacerbation. PubMedInterstitial Lung Disease - StatPearls - NCBI Bookshelf

Findings that should trigger escalation in fibrosing ILD. PubMedInterstitial Lung Disease - StatPearls - NCBI Bookshelfcdn clinicaltrialsClinical Trial Protocolcdn clinicaltrials[PDF] Galactic-1 Study Protocol - Clinical Trialspubs rsnaIdiopathic Pulmonary Fibrosis: Physiologic Tests ...
FindingInterpretationImmediate next step
FVC below 80% predicted and decliningSupports transplant-listing consideration in ILD. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfRefer or re-engage a lung-transplant program while continuing ILD-directed management. PubMedInterstitial Lung Disease - StatPearls - NCBI Bookshelf
DLCO below 40% predictedAdvanced physiologic impairment supporting transplant-listing consideration. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfAssess oxygenation, comorbid pulmonary hypertension, and transplant candidacy. PubMedInterstitial Lung Disease - StatPearls - NCBI Bookshelfcdn clinicaltrialsClinical Trial Protocol
6MWT below 250 m or decliningFunctional decline supporting transplant-listing consideration. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfReassess exertional oxygenation and refer for transplant evaluation if not already completed. PubMedInterstitial Lung Disease - StatPearls - NCBI Bookshelf
Acute worsening within 30 days with new bilateral ground-glass opacity or consolidationRaises concern for acute exacerbation after infection and alternative causes are excluded. cdn clinicaltrials[PDF] Galactic-1 Study Protocol - Clinical TrialsUrgently evaluate oxygenation, infection, and competing cardiopulmonary causes. cdn clinicaltrials[PDF] Galactic-1 Study Protocol - Clinical Trials
FVC-percent-predicted/DLCO-percent-predicted ratio at least 1.8May indicate a need to evaluate for pulmonary hypertension in an appropriate clinical context. cdn clinicaltrialsClinical Trial ProtocolConsider right-heart catheterization when pulmonary hypertension assessment will alter management. cdn clinicaltrialsClinical Trial Protocol

Treatment priorities

Direct management to the confirmed mechanism and severity trajectory

Restriction is a physiologic pattern; treatment follows the cause rather than the PFT label.

For extrapulmonary restriction, manage the identified mechanical or neuromuscular driver rather than initiating ILD-directed therapy. Obesity-associated physiology often includes isolated ERV reduction, whereas neuromuscular disease can produce low TLC and vital capacity with preserved residual volume; chest-wall and pleural disorders require structural characterization on examination and imaging. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf

For fibrosing ILD, establish the disease subtype through HRCT, exposure review, autoimmune assessment, and multidisciplinary interpretation before selecting disease-directed treatment. Antifibrotic therapy with nintedanib or pirfenidone slows lung-function decline in progressive fibrosing ILD, but agent selection, labeling status, contraindications, and dosing require confirmation against current prescribing information and the specific ILD diagnosis. PubMedManagement of Progressive Fibrosing Interstitial Lung ...

Provide oxygen when clinically indicated by resting or exertional hypoxemia and incorporate pulmonary function, oxygenation, and 6MWT into longitudinal management. For progressive disease, transplant referral is not a last-resort intervention: early referral is recommended at IPF diagnosis because wait-list time can limit access to transplantation. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfPubMedManagement of Progressive Fibrosing Interstitial Lung ...

Cause-directed management priorities in restrictive lung disease. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfPubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelfcdn clinicaltrials'-1lll1v IngelheimPubMedManagement of Progressive Fibrosing Interstitial Lung ...clinicaltrialsStudy Details | NCT06855329 | PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis | ClinicalTrials.govclinicaltrialsStudy Details | NCT06416163 | FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion | ClinicalTrials.gov
Confirmed categoryManagement priorityMonitoring focus
Obesity, chest-wall, pleural, or neuromuscular restrictionTreat the extrapulmonary mechanical or neuromuscular disorder; do not use an ILD pathway without corroborating imaging or diffusion impairment. PubMedRestrictive Lung Disease - StatPearls - NCBI BookshelfPubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI BookshelfTLC, VC/FVC, symptoms, and the underlying disorder's trajectory. PubMedIdiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf
IPF or progressive fibrosing ILDConsider antifibrotic therapy with nintedanib or pirfenidone and assess early transplant referral. PubMedInterstitial Lung Disease - StatPearls - NCBI BookshelfPubMedManagement of Progressive Fibrosing Interstitial Lung ...FVC, DLCO, oxygenation, 6MWT, HRCT progression, and acute exacerbations. PubMedInterstitial Lung Disease - StatPearls - NCBI Bookshelfcdn clinicaltrials'-1lll1v Ingelheim
CTD-ILDCoordinate pulmonary and systemic disease assessment because nonpulmonary comorbidity may confound severity measures. BMJConnective tissue disease related interstitial lung ... - ThoraxPFT trend, oxygenation, HRCT, and CTD activity or comorbidity burden. BMJConnective tissue disease related interstitial lung ... - ThoraxPubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )
Exposure-related fibrosing ILDIdentify and remove relevant environmental, occupational, or drug exposure while confirming subtype through integrated assessment. cdn clinicaltrials'-1lll1v IngelheimclinicaltrialsStudy Details | NCT06855329 | PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis | ClinicalTrials.govSymptoms, PFTs, oxygenation, and radiographic progression after exposure intervention. PubMedManagement of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP )cdn clinicaltrials'-1lll1v Ingelheim

References

  1. Progressive fibrosing interstitial lung disease: clinical ... — www.thelancet.com · www.thelancet.com
  2. Multicentre evaluation of multidisciplinary team meeting ... — www.thelancet.com · www.thelancet.com
  3. Connective tissue disease related interstitial lung ... - Thorax — thorax.bmj.com · thorax.bmj.com
  4. from childhood to adult interstitial lung disease — thorax.bmj.com · thorax.bmj.com
  5. Machine learning in radiology: the new frontier in interstitial ... — www.thelancet.com · www.thelancet.com
  6. Interstitial Lung Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov · www.ncbi.nlm.nih.gov
  7. Management of Interstitial Lung Diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP ) — pmc.ncbi.nlm.nih.gov · pmc.ncbi.nlm.nih.gov
  8. Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents — pmc.ncbi.nlm.nih.gov · pmc.ncbi.nlm.nih.gov
  9. Update in diagnosis and management of interstitial lung disease — pmc.ncbi.nlm.nih.gov · pmc.ncbi.nlm.nih.gov
  10. Current diagnosis, epidemiology, and management of interstitial lung abnormalities — pmc.ncbi.nlm.nih.gov · pmc.ncbi.nlm.nih.gov
  11. Restrictive Lung Disease - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov · www.ncbi.nlm.nih.gov
  12. Idiopathic Pulmonary Fibrosis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov · www.ncbi.nlm.nih.gov
  13. Nonspecific Interstitial Pneumonia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov · www.ncbi.nlm.nih.gov
  14. Using Bronchoscopic Lung Cryobiopsy and a Genomic ... — journal.chestnet.org · journal.chestnet.org
  15. Online Supplement — journal.chestnet.org · journal.chestnet.org
  16. d7811c00001-sap-ed-2_8Aug2024_Redacted — cdn.clinicaltrials.gov · cdn.clinicaltrials.gov
  17. Clinical Trial Protocol — cdn.clinicaltrials.gov · cdn.clinicaltrials.gov
  18. Pulmonary Function Tests for the Radiologist — pubs.rsna.org · pubs.rsna.org
  19. [PDF] Galactic-1 Study Protocol - Clinical Trials — cdn.clinicaltrials.gov · cdn.clinicaltrials.gov
  20. '-1lll1v Ingelheim — cdn.clinicaltrials.gov · cdn.clinicaltrials.gov
  21. Idiopathic Pulmonary Fibrosis: Physiologic Tests ... — pubs.rsna.org · pubs.rsna.org
  22. Management of Progressive Fibrosing Interstitial Lung ... — pubmed.ncbi.nlm.nih.gov · pubmed.ncbi.nlm.nih.gov
  23. Study Details | NCT06855329 | PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis | ClinicalTrials.gov — clinicaltrials.gov · clinicaltrials.gov
  24. Study Details | NCT06416163 | FIBRotic Interstitial Lung Disease With Nocturnal hypOXaemia and EXercise Induced desaTuRAtion | ClinicalTrials.gov — clinicaltrials.gov · clinicaltrials.gov